IL6 and COVID-19: These compounds also demonstrated favorable blood-brain barrier permeability and pharmacokinetic profiles, suggesting their potential as therapeutic antagonists for treating prolonged COVID-related neuroinflammation.<h4>Conclusion</h4>IL-6, IL-10, and SP are found to be deregulated in long COVID-19 leading to neurophysiological sequelae.